Efficacy of Using Interleukin-2 in Antiretroviral Naïve HIV Patients (ANRS119)

StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 2 versions Re-verified since Dec 21, 2011, no change to tracked fieldsv7-v8
  2. Trial status: Terminated to Completed
    • Primary completion date: Nov 2006
    • Study title expanded, about 1 word
    v6
  3. Trial status: Active, Not Recruiting to Terminated
    • Study completion date: Nov 2006
    v5
  4. Re-verified, no change to tracked fieldsv4
  5. Study Identification, Study Statusv3
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Interleukin-2 (IL-2) increases the number of CD4 cells in HIV-1 infected patients under highly active antiretroviral therapy (HAART) with a CD4 cell count over 200/mm3, but its activity in patients without antiretroviral therapy is unknown. This study will test the efficacy and safety of IL-2 in naïve patients with a CD4 count between 300 and 500/m3.
Trial Details
NCT Number NCT00120185
Lead Sponsor French National Agency for Research on AIDS and Viral Hepatitis
Collaborators: Chiron Corporation
Conditions
(from sponsor)		 HIV Infections
Related terms HIV Infections
Enrollment 130 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov